ABBV
A very expensive game of keep-away
AbbVie woke up with a prettier patent picture today. The company said it settled litigation with all generic manufacturers challenging Rinvoq, its fast-growing immunology drug, and that deal should block U.S. generic competition until April 2037.
That’s not just a legal win. It’s a revenue runway. Rinvoq, along with Skyrizi, is one of the two big brands carrying AbbVie into the post-Humira era — aka the part where the company has to prove it can keep the cash machine humming without its former mega-blockbuster doing the heavy lifting.
Why investors cared
Humira used to be the whole party. Now AbbVie is trying to make sure the new hosts — Rinvoq and Skyrizi — can keep the lights on. The longer Rinvoq stays protected, the longer AbbVie gets to charge premium prices without a swarm of cheaper copycats showing up at the door.
And the market clearly heard the message. Shares were up more than 4% as investors digested the news, which is basically Wall Street’s version of a thumbs-up emoji.
The fine print, because patents are weird
AbbVie didn’t name the generic makers in the SEC filing, but it said the settlement covers the companies that had been challenging Rinvoq’s patents. The article notes AbbVie has been in litigation with several familiar generic names, including Aurobindo, Hetero Labs, Intas Pharmaceuticals, Sandoz, and Sun Pharma.
Big picture: this is the kind of legal news biotech investors love because it’s less about courtroom drama and more about protecting a blockbuster’s paycheck for another decade plus. In pharma, time really is money — and AbbVie just bought a lot of it.